Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report

ABSTRACT Background Coronavirus disease 2019 (COVID-19) is associated with diffuse lung damage. Corticosteroids may modulate immune-mediated lung injury and reducing progression to respiratory failure and death. Methods The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, adaptive, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. We report the preliminary results for the comparison of dexamethasone 6 mg given once daily for up to ten days vs. usual care alone. The primary outcome was 28-day mortality. Results 2104 patients randomly allocated to receive dexamethasone were compared with 4321 patients…

• BA
  Bill and Melinda Gates Foundation
• UR
  UK Research and Innovation

  Award: MC_PC_19056
• NI
  National Institute for Health and Care Research

  Award: MC_PC_19056
• UO
  University of Oxford
• PH
  Public Health England
• DF
  Department for International Development
• MR
  Medical Research Council

  Awards: MC_UU_0002/14, MC_UU_00017/3, MC_PC_20062, MC_PC_19056
• NO
  NIHR Oxford Biomedical Research Centre
• NN
  NIHR Nottingham Biomedical Research Centre